Status:

COMPLETED

Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Healthy

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

Bioavailability study comparing two new nilotinib tablet formulations to an established nilotinib capsule formulation in healthy volunteers

Eligibility Criteria

Inclusion

  • Inclusion
  • Healthy adult male (18 - 55 yrs) and sterile or post menopausal female subjects
  • Body weight must be ≥50 kg and \<100 kg, with a body mass index (BMI) \>18 but \<33.
  • Laboratory parameter values must fall within the normal range
  • Exclusion
  • Female who is pregnant or breast feeding.
  • Contraindication to receiving nilotinib.
  • Smokers or user of tobacco products
  • A past medical history of clinically significant Electrocardiogram abnormalities, or a history/family history of long QT-interval syndrome.
  • Other protocol-defined inclusion/exclusion criteria may apply

Exclusion

    Key Trial Info

    Start Date :

    June 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT00418769

    Start Date

    June 1 2006

    Last Update

    December 9 2020

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.